Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617765 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29676707 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL335349 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL335622 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29350839 | 1.00 | TAAR1 (0.56) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16345210 | 0.98 | TAAR1 (0.55) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL12495550 | 0.98 | TAAR1 (0.55) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL10781087 | 0.85 | AOC3 (0.54) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL10781776 | 0.85 | AOC3 (0.54) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL8204131 | 0.84 | TAAR1 (0.53) | TAAR1AOC3ALDH1A1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925626-B | Novel aporphine compound and preparation method and application thereof | 中国药科大学 | 2025-06-13 | — | — | CN | claimed |
| CN-118420612-A | Target protein degradation compound based on CDK4/6 inhibitor and preparation method and application thereof | 沈阳药科大学 | 2024-08-02 | — | — | CN | claimed |
| CN-115894365-B | Synthesis method of tetrahydroisoquinoline compound and intermediate thereof | 南方科技大学坪山生物医药研究院 | 2024-07-02 | — | — | CN | claimed |
| CN-117560937-A | Perovskite solar cell based on 3-methoxy phenethylamine passivating agent and preparation method thereof | 常州大学 | 2024-02-13 | — | — | CN | claimed |
| CN-114804989-B | Purification method and racemization recycling of rivastigmine key chiral intermediate | 华中科技大学 | 2023-12-26 | — | — | CN | claimed |
| CN-117082953-A | Optoelectronic device and method for producing the same | 天合光能股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-3688131-B1 | COMPOSITIONS AND METHODS FOR PREVENTING COLLAPSE OF HIGH ASPECT RATIO STRUCTURES DURING DRYING | VERSUM MAT US LLC (US) | 2023-08-09 | — | — | EP | claimed |
| CN-115925626-A | Novel aporphine compound and preparation method and application thereof | 中国药科大学 | 2023-04-07 | — | — | CN | claimed |
| EP-4157233-A1 | TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES | Zydus Lifesciences Limited (IN) | 2023-04-05 | — | — | EP | claimed |
| CN-115894365-A | Synthesis method of tetrahydroisoquinoline compound and intermediate thereof | 南方科技大学坪山生物医药研究院 | 2023-04-04 | — | — | CN | claimed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-0848065-B1 | Method for improving optical purity of an amine compound | SUMITOMO CHEMICAL CO (JP) | 2003-04-02 | — | — | EP | claimed |
| US-5965432-A | PREFERENTIALLY METABOLIZING (S) ENANTOMORPH OF MIXTURE USING CULTURE OF ARTHROBACTER, CULTURE LIQUID, GEL IMMOBILIZED CELLS, FREEZE-DRIED OR ACETONE-DRIED CELLS, GROUND OR AUTODIGESTED CELLS, ULTRASONIC TREATED OR EXTRACTED CELLS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | claimed |
| EP-0848065-A2 | Method for improving optical purity of an amine compound | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-06-17 | — | — | EP | claimed |
| US-5648540-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1997-07-15 | — | — | US | claimed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | claimed |
| EP-0474200-B1 | Process for the resolution of racemic 2,2-dimethyl cyclopropane carboxylic acid | LONZA AG (CH) | 1994-12-14 | — | — | EP | claimed |
| US-5166417-A | PROCESS FOR RESOLUTION OF RACEMATES OF 2,2-DIMETHYLCYCLOPROPANECARBOXYLIC ACID | LONZA LTD. (CH) | 1992-11-24 | — | — | US | claimed |
| EP-0474200-A2 | Process for the resolution of racemic 2,2-dimethyl cyclopropane carboxylic acid | LONZA AG (CH) | 1992-03-11 | — | — | EP | claimed |